Literature DB >> 20332213

HuR knockdown changes the oncogenic potential of oral cancer cells.

Wataru Kakuguchi1, Tetsuya Kitamura, Takeshi Kuroshima, Makoto Ishikawa, Yoshimasa Kitagawa, Yasunori Totsuka, Masanobu Shindoh, Fumihiro Higashino.   

Abstract

HuR binds to AU-rich element-containing mRNA to protect them from rapid degradation. Here, we show that knockdown of HuR changes the oncogenic properties of oral cancer cells. Oral squamous cell carcinoma cell lines, HSC-3 and Ca9.22, which express HuR protein and cytoplasmic AU-rich element mRNA more abundantly than normal cells, were subjected to HuR knockdown. In the HuR-knockdown cancer cells, the cytoplasmic expression of c-fos, c-myc, and COX-2 mRNAs was inhibited compared with those in cells that had been transfected with a control small interfering RNA, and the half-lives of these mRNAs were shorter than those of their counterparts in the control cells. HuR-knockdown cells failed to make colonies in soft agar, suggesting that the cells had lost their ability for anchorage-independent cell growth. Additionally, the motile and invasive activities of the cells decreased remarkably by HuR knockdown. Furthermore, the expression of cell cycle-related proteins, such as cyclin A, cyclin B1, cyclin D1, and cyclin-dependent kinase 1, was reduced in HuR-knockdown cancer cells, and HuR bound to cdk1 mRNA to stabilize it. These findings suggest that HuR knockdown changes the features of oral cancer cells, at least in part, by affecting their cell cycle and shows potential as an effective therapeutic approach. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332213     DOI: 10.1158/1541-7786.MCR-09-0367

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  33 in total

1.  Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2.

Authors:  C Lucchesi; M S Sheikh; Y Huang
Journal:  Oncogene       Date:  2015-10-05       Impact factor: 9.867

2.  Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress.

Authors:  Sudha Talwar; Junfei Jin; Brittany Carroll; Angen Liu; Marion Boyd Gillespie; Viswanathan Palanisamy
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability.

Authors:  Jingjie Zhang; Weiming Ouyang; Jingxia Li; Dongyun Zhang; Yonghui Yu; York Wang; Xuejun Li; Chuanshu Huang
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-28       Impact factor: 4.219

4.  Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.

Authors:  Elizabeth A Van Tubergen; Rajat Banerjee; Min Liu; Robert Vander Broek; Emily Light; Shiuhyang Kuo; Stephen E Feinberg; Amanda L Willis; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Francis P Worden; Keith L Kirkwood; Nisha J D'Silva
Journal:  Clin Cancer Res       Date:  2013-01-24       Impact factor: 12.531

5.  PIASxα ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase.

Authors:  Weibin Wang; Yifan Chen; Shuya Wang; Ningguang Hu; Zhengyi Cao; Wengong Wang; Tanjun Tong; Xiaowei Zhang
Journal:  J Biol Chem       Date:  2013-12-16       Impact factor: 5.157

6.  HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Authors:  Aldona Jakstaite; Aurelija Maziukiene; Giedre Silkuniene; Kristina Kmieliute; Antanas Gulbinas; Zilvinas Dambrauskas
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

7.  Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.

Authors:  Ranganayaki Muralidharan; Anish Babu; Narsireddy Amreddy; Akhil Srivastava; Allshine Chen; Yan Daniel Zhao; Uday B Kompella; Anupama Munshi; Rajagopal Ramesh
Journal:  Mol Cancer Ther       Date:  2017-06-01       Impact factor: 6.261

8.  HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis.

Authors:  Michaela Lang; David Berry; Katharina Passecker; Ildiko Mesteri; Sabin Bhuju; Florian Ebner; Vitaly Sedlyarov; Rayko Evstatiev; Kyle Dammann; Alexander Loy; Orest Kuzyk; Pavel Kovarik; Vineeta Khare; Martin Beibel; Guglielmo Roma; Nicole Meisner-Kober; Christoph Gasche
Journal:  Cancer Res       Date:  2017-02-20       Impact factor: 12.701

Review 9.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

10.  Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.

Authors:  Narsireddy Amreddy; Anish Babu; Janani Panneerselvam; Akhil Srivastava; Ranganayaki Muralidharan; Allshine Chen; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Nanomedicine       Date:  2017-11-16       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.